EGFR and non-small cell lung carcinoma: Yen et al. also demonstrated that the survival benefits of combining thoracic RT (45 Gy at least) and EGFR tyrosine kinase inhibitor (TKI) in metastatic NSCLC patients with sensitizing EGFR alterations (19).